Thus, targeting CD40 in GBM has been proposed, partly to stimulate immune responses, partly based on reported slightly faster progression among higher CD40 expressing gliomas, including GBMs [68], although levels of CD40 are generally low in GBM compared to some other cancers [69] and among GBM cell lines [70]. The gene discussed is CD40; the disease is glioma.